Cesium-131 prostate brachytherapy: A single institutional long-term experience.
| Autor: | Benoit RM; Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA., Horne ZD; Department of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA., Houser CJ; Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA., Smith RP; Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA., Beriwal S; Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA. Electronic address: beriwals@upmc.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Brachytherapy [Brachytherapy] 2020 May - Jun; Vol. 19 (3), pp. 298-304. Date of Electronic Publication: 2020 Apr 02. |
| DOI: | 10.1016/j.brachy.2020.02.006 |
| Abstrakt: | Aims: To report on the PSA outcomes in men undergoing prostate seed implant (PSI) with Cesium-131 at a single institution. Materials and Methods: All patients who underwent prostate brachytherapy with Cesium-131 ( 131 Cs) at our institution and had the potential for at least 24 months of follow up were included in this study. Results are reported for the by NCCN risk group (low, low/high-intermediate, and high), as well as by treatment received (monotherapy, combination external beam radiation + PSI, or trimodal therapy with androgen deprivation). The Phoenix definition (absolute nadir plus 2 ng/mL) was used to define biochemical freedom from disease (BFD). Results: Eight hundred and six men have undergone prostate brachytherapy with Cesium-131 at our institution, and 669 men were included in analysis. Median follow up was 60.0 months (range: 0-144 months). According to NCCN risk categories, 29.9% were low-, 55.6% intermediate-, and 14.5% high-risk. Using the Phoenix criteria, 5/10-year BFD was 97.1/95.3% for patients in the low-risk category, 94.0/90.1% for patients in the intermediate-risk category, and 86.2/56.6% for patients in the high-risk category. PSA ≤0.2 ng/dL at 4 years was predictive of 10 year biochemical control: 96.3% vs 70.4%, p < 0.001. Conclusions: The present study demonstrates that prostate brachytherapy with 131 Cs achieves excellent long-term biochemical control. (Copyright © 2020 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|